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Clinical samples were also challenged on both platforms Among the 86 clinical samples tested 42 wereAim of this study. We have evaluated the Abbott RealTime EBV and CMV quantitative assays performed on . ,
quantified by the Abbott RealTime CMV assay but only 23 with the Starlet/Diagenode method (including 8the fully automated Abbott m2000 platform. This platform offers the possibility to run both assays for a unique
samples undetected). Twenty-two clinical samples were quantified by both methods showing a higher
a erage iral load of 0 79 log IU/mL for the Starlet/Diagenode method as ill strated b the CMV iral load
sample in a single run using a double extraction.
v v . 10 u y v
follow-up of a patient.
Design. We have compared the performance of the Abbott system to our currently semi-automated method
consisting of a NucleoMag® Blood 200 μL (Macherey-Nagel) DNA extraction automated on a Starlet (Hamilton) S l / i d
platform followed by manually processed real-time PCRs using the CMV and EBV Diagenode assays (H- 6,00 CMV viral loads follow‐up using both 
tar et D ageno e CMV 
(nb of samples)
DiaCMVQ and H-DiaEBVQ™, respectively) on a ABI7500 (=Starlet/Diag). Serial dilutions of CMV and EBV
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Doted lines = LOQ of the tests
Red dots on the doted lines are viral loads under the LOQ
Comparison of CMV detection and quantification in clinical
samples using Abbott m2000 vs Starlet/Diagenode platforms
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Among the 86 clinical samples tested, 42 were quantified by the Abbott RealTime EBV assay and 34 with the
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Accuracy: 0 21 log IU/mL average viral load of 0.18 log10 IU/mL with the Starlet/Diagenode method as illustrated by the EBV viral load
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Accuracy:    0,27 log10 IU/mL
Pi k d th d li it f tifi ti (LOQ) / Bl d t tifi ti t 100%
Comparison of EBV detection and quantification in clinical
samples using Abbott m2000 vs Starlet/Diagenode platforms
CMV WHO Standard (log10 IU/mL) EBV WHO Standard (log10 IU/mL) Doted lines = LOQ of the tests
Red dots on the doted lines are viral loads under the LOQ
n  zones = un er e announce  m  o  quan ca on   ue o s: quan ca on ra e = 
R lt Th Abb tt R lTi CMV hibit hi h iti it i i ll hi h Conclusions. The Abbott RealTime CMV and EBV quantitative assays performed on the fully 
automated Abbott m2000 platform are accurate sensitive and precise and can be used routinely for the
esu s. e o ea me assay ex s a g er sens v y, prec s on as we as a g er
quantification rate at low viral loads than our routine test while the Abbott RealTime EBV assay performances      ,           
quantification of those viruses in blood. Furthermore, this platform allows the processing of both assays in are similar in terms of sensitivity to those of the Nucleomag/Diagenode EBV test, but is more precise than this
l t Th Abb tt CMV d EBV t th ti t t b t hibit li ht
C i ht © 2017 S B t t l Th th d l th t th h fli t f i t t Abb tt EBV d CMV t h b id d b Abb tt M l l
parallel which is valuable for the management of the workflow in clinical laboratory settings.a e one. e o an assays are more accura e an our rou ne es s u ex a s g
underestimation of the viral loads (-0.29 and -0.21 log IU/mL respectively).
opyr g     on ems e  a  . e au ors ec are a ey ave no con c o  n eres . o   an   reagen s ave een prov e y o  o ecu ar
